Effector Therapeutics Stock Current Valuation
| EFTRWDelisted Stock | USD 0 0.00 0.00% |
Valuation analysis of EFFECTOR Therapeutics helps investors to measure EFFECTOR Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that EFFECTOR Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of EFFECTOR Therapeutics is based on 3 months time horizon. Increasing EFFECTOR Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the EFFECTOR pink sheet is determined by what a typical buyer is willing to pay for full or partial control of EFFECTOR Therapeutics. Since EFFECTOR Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of EFFECTOR Pink Sheet. However, EFFECTOR Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.001 | Real 9.5E-4 | Hype 0.001 | Naive 0.00993 |
The intrinsic value of EFFECTOR Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence EFFECTOR Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of EFFECTOR Therapeutics helps investors to forecast how EFFECTOR pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of EFFECTOR Therapeutics more accurately as focusing exclusively on EFFECTOR Therapeutics' fundamentals will not take into account other important factors: EFFECTOR Therapeutics Company Current Valuation Analysis
EFFECTOR Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, EFFECTOR Therapeutics has a Current Valuation of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
EFFECTOR Therapeutics is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about (9.05 Million). EFFECTOR Therapeutics adds roughly 0.0 in current valuation claiming only tiny portion of equities under Health Care industry.EFFECTOR Fundamentals
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 | |||
| Number Of Shares Shorted | 18.44 K | |||
| EBITDA | (33.73 M) | |||
| Net Income | (35.81 M) | |||
| Total Debt | 19.45 M | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (29.55 M) | |||
| Earnings Per Share | (0.91) X | |||
| Number Of Employees | 14 | |||
| Beta | 0.62 | |||
| Total Asset | 20.54 M | |||
| Retained Earnings | (179.38 M) | |||
| Working Capital | (5.96 M) | |||
| Net Asset | 20.54 M |
About EFFECTOR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EFFECTOR Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EFFECTOR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EFFECTOR Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |